NCT06377085View on ClinicalTrials.gov

Repurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral Palsy

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

July 31, 2027

Conditions
Cerebral PalsyContracture
Interventions
DRUG

Placebo for the AZA 10mg/m^2

Placebo control group for the 10mg/m\^2, one-time subcutaneous injection without the active treatment.

DRUG

Placebo for the AZA 20mg/m^2

Placebo control group for the 20mg/m\^2, one-time subcutaneous injection without the active treatment.

DRUG

Placebo for the AZA 35mg/m^2

Placebo control group for the 35mg/m\^2, one-time subcutaneous injection without the active treatment.

DRUG

Placebo for the AZA 75mg/m^2

Placebo control group for the 75mg/m\^2, one-time subcutaneous injection without the active treatment.

DRUG

5-Azacytidine 10mg/m^2

5-Azacytidine 10mg/m\^2, one-time subcutaneous injection

DRUG

5-Azacytidine 20mg/m^2

5-Azacytidine 20mg/m\^2, one-time subcutaneous injection

DRUG

5-Azacytidine 35mg/m^2

5-Azacytidine 35mg/m\^2, one-time subcutaneous injection

DRUG

5-Azacytidine 75mg/m^2

5-Azacytidine 75mg/m\^2, one-time subcutaneous injection

Trial Locations (1)

92123

Rady Children's Hospital - San Diego, San Diego

All Listed Sponsors
collaborator

Rady Children's Hospital, San Diego

OTHER

lead

Shirley Ryan AbilityLab

OTHER